Supernus Pharmaceuticals | SUPN - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Abbott USD 299M 231M 2026-06
ANI Pharmaceuticals USD 3.64M 775K 2026-06
Aurora Cannabis CAD 230K 1.88M 2026-03
Bristol-Myers Squibb USD 407M 4M 2026-06
Canopy Growth CAD 12.31M 4.97M 2026-03
Cara Therapeutics -89.64M 128.67M 2025-12
Corcept Therapeutics USD 888.7M 73.82M 2026-06
Eisai JPY 1.96B 409M 2026-06
Eli Lilly USD 114.7M 134.3M 2025-09
Novo Nordisk DKK 1.5B 28M 2026-06
Pacira USD 3.62M 77K 2026-06
Perrigo USD 7.61B 373.8M 2026-06
Pfizer USD 667M 4M 2026-06
Supernus Pharmaceuticals USD 910K 278K 2023-06
United Therapeutics USD 2.9M 200K 2026-06
Xeris Pharmaceuticals USD 6.88M 269K 2026-03